Free Trial

Moderna Positivity, Veto Negativity

EGB SUMMARY

It has been a day dictated by two key events for EGBs so far.

  • First, Moderna's vaccine showed an efficacy rate of 94.5% in its trials - slightly better than results seen from the Pfizer trial. However, in a big logistical difference, the Moderna vaccine can be stored in a conventional freezer for six months and then in a fridge for up to 30 days. This contrasts to the -70C conditions the Pfizer vaccine must be stored at. This saw Bunds sell off as risk rallied and peripheral spreads narrow. BTP-Bund spreads move to their tightest levels since mid-2018.
  • Second, as noted in the 14:38GMT bullet, Poland and Hungary have vetoed the EU's long-term budget and Next Gen EU EUR750bln COVID recovery fund. This has seen Bunds and peripheral spreads reverse their earlier risk-on moves with most EGBs now fairly close to flat on the day.
  • Bund futures are up 0.10 today at 175.04 with 10y Bund yields down -0.3bp at -0.552% and Schatz yields up 0.2bp at -0.732%.
  • BTP futures are up 0.06 today at 150.65 with 10y yields down -0.7bp at 0.657% and 2y yields down -0.7bp at -0.375%.
  • OAT futures are up 0.16 today at 169.70 with 10y yields down -0.8bp at -0.318% and 2y yields up 0.8bp at -0.678%.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.